Viatris Inc. (VTRS): Business Model Canvas [June-2026 Updated]

Get a ready-made, research-based Business Model Canvas of Viatris Inc. that shows you how the company creates value through affordable medicines, a broad generic and specialty portfolio, and supply to about 1 billion patients across 165 countries. You'll see the core partnerships, activities, resources, channels, customer segments, revenue streams, and cost drivers behind its global manufacturing footprint of 27 sites, plus the strategic focus on ophthalmology, dermatology, and gastroenterology, so you can use it as a practical study aid for essays, case studies, presentations, and business analysis.

Viatris Inc. - Canvas Business Model: Key Partnerships

$3.335 billion is the most important partnership-linked transaction in Viatris Inc.'s biosimilars strategy, because it reshaped the company's role from direct biosimilars operator into a partner with continuing commercial and equity exposure.

Partner	Relationship type	Real-life number or amount	Business impact
Biocon Biologics	Biosimilars transaction and commercial collaboration	$3.335 billion	Converted a business line into cash plus equity exposure
Biocon Biologics	Cash consideration	$2 billion	Provided immediate liquidity
Biocon Biologics	Equity consideration	12.55%	Kept Viatris linked to future value creation
FDA	Regulatory gatekeeper	1 approval pathway for U.S. launches	Determines market entry timing and labeling
PMDA	Regulatory gatekeeper	1 approval pathway for Japan launches	Determines market entry timing in Japan

Biocon Limited / Biocon Biologics is the most visible partnership in Viatris Inc.'s Business Model Canvas. The economics matter because the biosimilars transaction included $2 billion in cash and a 12.55% equity stake, so Viatris did not just exit a business line; it kept a financial interest in the asset's future performance.

This matters for the canvas because key partnerships are not only about operations. They also affect capital allocation, risk transfer, and future cash flows. A cash component improves balance-sheet flexibility, while an equity stake preserves upside if the biosimilars platform grows.

• $3.335 billion total consideration tied to the biosimilars transaction
• $2 billion cash that could support debt reduction, dividends, or reinvestment
• 12.55% continuing equity interest that ties Viatris to long-term value creation

For academic work, this partnership is useful because it shows how a pharmaceutical company can use a divestiture-plus-equity structure instead of a simple sale. That structure changes the business model from direct ownership to shared economic exposure.

FDA and PMDA regulatory bodies are not commercial partners, but they function as essential external dependencies. Viatris Inc. cannot launch many products in the U.S. without FDA approval, and it cannot launch in Japan without PMDA approval. In the business model canvas, these bodies shape access to revenue, because regulatory timing can move launches by quarters or years.

The practical value of these relationships is measurable in time and cost, even when no single dollar amount is disclosed. Every approval cycle affects development spending, inventory planning, and expected cash flow timing. In plain English, the regulator decides when a future cash flow can start.

• FDA controls U.S. market entry for prescription medicines and biosimilars
• PMDA controls Japanese review and approval pathways
• Approval timing affects launch timing, revenue timing, and patent-exposure timing

For a case study, these regulatory partnerships matter because they are repeated relationships, not one-time events. Viatris Inc. must keep quality systems, pharmacovigilance, manufacturing controls, and dossier preparation aligned with both agencies across multiple products.

Global manufacturing and supply chain partners matter because Viatris Inc. runs a complex multi-country supply network for active pharmaceutical ingredients, finished-dose manufacturing, packaging, and distribution support. In this model, partners are needed to reduce single-site risk, support local-market supply, and keep medicines available when demand shifts.

Supply chain partnerships matter financially because they influence gross margin. Gross margin is revenue after direct product costs. If a company has to use more external manufacturing, expedited freight, or dual sourcing, product cost rises and margin falls.

In the pharmaceutical industry, this relationship is especially important for:

• Active pharmaceutical ingredient sourcing
• Contract manufacturing of selected dosage forms
• Packaging and serialization support
• Cold-chain and temperature-controlled logistics

The strategic value is resilience. A diversified manufacturing footprint lowers the chance that one facility outage will interrupt supply across multiple markets. That matters because even short interruptions can affect revenue, customer trust, and regulatory standing.

Healthcare distributors and pharmacy networks are the main commercial link between Viatris Inc. and patients in many markets. These channels include wholesalers, retail pharmacy chains, hospital systems, and group purchasing organizations. They matter because a medicine that is approved and manufactured still cannot generate revenue until it reaches the dispensing network.

For academic analysis, these partnerships are important because they shape bargaining power. Large distributors can press for lower prices, faster fill rates, and broader product availability. That can support volume, but it can also compress net selling prices.

• Wholesalers move product in large volume to downstream customers
• Retail pharmacy networks convert prescriptions into final sales
• Hospitals and health systems drive demand for selected injectable and specialty products
• Purchasing groups influence contract terms and reimbursement access

The key number to track here is not always a disclosed partnership fee. It is the spread between list price and net price, because distributor and pharmacy economics determine how much of the top-line sale reaches Viatris Inc. as net revenue.

Institutional shareholders are a different kind of partnership because they are not operating partners, but they shape governance, capital discipline, and strategic pressure. In Viatris Inc.'s case, large institutions matter because they influence voting outcomes, board accountability, and expectations around buybacks, dividends, debt, and portfolio reshaping.

Institutional ownership also matters because pharmaceutical companies often depend on long-term capital to fund litigation, compliance, product launches, and restructuring. Large shareholders tend to focus on cash generation, leverage, and execution quality.

• Large asset managers can affect voting outcomes on directors and compensation
• Long-term holders can support strategic patience during restructuring
• Active managers can push for asset sales, margin expansion, or capital returns

In business model terms, institutional shareholders do not deliver medicines or regulatory approvals, but they do shape the capital structure that supports them. That makes them a real key partnership layer for Viatris Inc., especially when the company is balancing debt, cash flow, and portfolio simplification.

Viatris Inc. - Canvas Business Model: Key Activities

$15.4 billion in 2023 net sales, $5.9 billion in adjusted EBITDA, and $2.9 billion in free cash flow show that Viatris Inc.'s key activities are built around volume manufacturing, regulatory execution, and cost control rather than high-margin innovation alone.

Key activity	Business purpose	Real-life scale indicators
Develop and file generic and specialty medicines	Build a pipeline of products that can win approvals, extend labels, and replace aging revenue streams	2023; global portfolio across generics and specialty medicines
Manufacture and supply medicines globally	Keep medicines available across many markets through a large manufacturing and supply network	2023; operations spanning multiple regions and markets
Secure regulatory approvals and label expansions	Obtain marketing authorization and broaden approved uses for existing products	2023; regulatory filings across multiple jurisdictions
Optimize portfolio and cut costs	Shift capital toward higher-value products and reduce structural expenses	$5.9 billion adjusted EBITDA in 2023
Manage divestitures and facility rationalization	Sell non-core assets and reduce manufacturing footprint where capacity is no longer needed	2023; continuing portfolio reshaping after the 2020 launch of Viatris Inc.

Developing and filing generic and specialty medicines is the core production and growth task. In practice, this means preparing dossiers, stability data, bioequivalence work, and manufacturing documentation for regulators. For a company with a broad portfolio, the activity matters because each approval can add revenue without the long development cycle of a new drug. Viatris Inc. uses this activity to support a portfolio that is commercially large and geographically broad, which lowers dependence on any single product.

Manufacturing and supply are just as important as product development. Medicines only create revenue when they can be produced reliably, released to quality standards, and shipped on time. For Viatris Inc., this is a global coordination task across active pharmaceutical ingredient sourcing, finished-dose production, quality testing, packaging, and distribution. In a business with $15.4 billion in annual net sales, even small supply disruptions can affect revenue, working capital, and customer trust.

• Maintain plant output for high-volume medicines
• Balance inventory against demand in multiple regions
• Manage quality release so batches can be sold
• Reduce shipping delays that can interrupt hospital, retail, and government supply

Securing regulatory approvals and label expansions is a separate activity from manufacturing because a product can only be sold within the exact scope approved by regulators. Label expansion can add new dosage forms, age groups, indications, or geographies. That matters strategically because it can raise the value of an existing molecule without requiring a completely new product launch. For a company like Viatris Inc., this is a lower-cost way to extend the life of a medicine and protect revenue from erosion.

Portfolio optimization and cost cutting are central to the economics of the business model. Viatris Inc. has to decide which products deserve investment, which products should be maintained with minimal spending, and which should be exited. The financial goal is to convert sales into cash efficiently. The reported $5.9 billion in adjusted EBITDA in 2023 shows the importance of operating discipline, because EBITDA is earnings before interest, taxes, depreciation, and amortization, a measure that helps show operating profit before non-cash charges and financing structure.

Key operating priorities in this area usually include:

• Reducing overlapping administrative and commercial costs
• Focusing capital on products with stronger returns
• Improving gross margin through procurement and manufacturing efficiency
• Lowering SG&A, which means selling, general, and administrative costs

Managing divestitures and facility rationalization is a direct way to shrink complexity. A divestiture is the sale of a business or product line. Facility rationalization means closing, consolidating, or resizing plants and support sites. These actions matter because they can lower fixed costs, simplify supply chains, and release cash, but they can also create restructuring charges and execution risk. In a company focused on broad medicine access and margin discipline, this activity supports a leaner operating model.

For academic work, the most useful point is that Viatris Inc.'s key activities are not just manufacturing. They connect regulatory execution, global supply reliability, portfolio decisions, and cost discipline into one operating system. That is why the company can report large-scale cash generation while still depending on constant product filings, approvals, and manufacturing control.

Late-stage operating priorities can be grouped like this:

• R&D and filings: product dossiers, approvals, and label changes
• Supply chain: production, quality, packaging, and distribution
• Commercial continuity: keeping approved medicines in market
• Structural change: divestitures, site closures, and cost reduction

These activities support a business that depends on scale, global reach, and cash conversion. They matter because a medicine portfolio only creates value if it can be approved, made, shipped, and kept profitable across multiple markets.

Viatris Inc. - Canvas Business Model: Key Resources

27-site global manufacturing footprint.

Commercial reach across 165 countries.

R&D pipeline assets in Phase 3 and NDA status.

Global centers in Pittsburgh, Shanghai, and Hyderabad.

Key resource	Real-life number	Business model role
Manufacturing footprint	27 sites	Production scale, supply continuity, and geographic diversification
Commercial reach	165 countries	Market access, distribution breadth, and sales coverage
Development pipeline	Phase 3 and NDA assets	Future product flow and lifecycle support
Global centers	3 centers	Coordination of strategy, operations, and development

27 manufacturing sites matter because Viatris depends on scale, regulatory compliance, and multi-region supply. A wider footprint reduces dependence on any single plant and supports continuity when one location faces quality, logistics, or local disruption issues.

• 27 sites support multi-country production
• 165 countries support broad product access
• 3 global centers support cross-border coordination
• Phase 3 assets support late-stage development value
• NDA assets support potential near-term regulatory filing activity

Commercial reach across 165 countries is a core resource because it gives Viatris a wide route to market. In a business model canvas, this resource supports the channels and customer relationships blocks because a larger country footprint usually means more distributors, regulators, reimbursement systems, and sales execution points to manage.

The R&D pipeline is a resource even in a large off-patent and complex-generic business because Phase 3 is the late-stage human testing phase and NDA is the New Drug Application stage. Those stages matter because they sit closest to possible commercial launch among development assets and can support future revenue replacement or expansion.

R&D stage	Meaning	Why it matters
Phase 3	Late-stage clinical testing	Closer to regulatory submission and potential commercialization
NDA	Regulatory filing stage	Signals a product is near a decision point for approval

The centers in Pittsburgh, Shanghai, and Hyderabad matter because they concentrate management, science, and operating expertise in three major locations. That structure helps Viatris coordinate global manufacturing, development, and commercial execution across time zones and regions.

Strong cash generation and liquidity are key resources because they fund working capital, capital spending, debt service, and development activity. In a capital-intensive healthcare business, cash generation matters because it gives the company room to keep manufacturing, quality systems, and pipeline work running without relying only on external financing.

The resource mix is strongest when these five items work together: 27 sites for supply, 165 countries for sales reach, Phase 3 and NDA assets for future growth, 3 global centers for coordination, and cash flow for funding and resilience.

Viatris Inc. - Canvas Business Model: Value Propositions

Viatris Inc. positions its value proposition around large-scale access, a wide medicine portfolio, and a shift toward higher-growth specialty areas. The core customer promise is simple: supply medicines to patients across a very large global footprint while using a mix of established generics and selective specialty assets.

Value proposition	Real-life metric or fact	Why it matters
Global access to medicines	About 1 billion patients	Shows the scale of patient reach behind the company's access model
International distribution	More than 165 countries and territories	Supports broad access across developed and emerging markets
Growth focus in specialty care	3 named focus areas: ophthalmology, dermatology, and gastroenterology	Signals where Viatris expects higher-growth product economics
Risk-balanced innovation model	Emphasis on late-stage and commercialized assets instead of only early-stage R&D	Reduces binary clinical trial risk compared with a pure biopharma model

Affordable medicines at global scale is the clearest part of the value proposition. Viatris sells medicines that are meant to be cheaper than many originator drugs, and it does so at a scale measured in about 1 billion patients. That matters because affordability only creates real value if the company can also distribute reliably across many markets. The company's reach across more than 165 countries and territories shows that this is not a local or regional model. It is built for high-volume access, which is important in academic analysis because scale can lower unit cost and widen patient access at the same time.

This affordability proposition matters to payers, governments, pharmacies, and hospital systems. It gives them a lower-cost sourcing option for medicines that are already widely needed. In business-model terms, Viatris captures value by selling at large volumes rather than relying only on high prices per unit. That is a different logic from many branded drug companies, where price per prescription does most of the work. Here, the value proposition depends on breadth, consistency, and procurement relevance.

• About 1 billion patients indicate a large addressable base for essential medicines.
• 165+ countries and territories show that the model depends on global regulatory and commercial execution.
• Low-cost access is strongest where buyers care about price, continuity, and availability at the same time.

Broad generic and specialty portfolio is the second major value proposition. Viatris does not depend on one product or one therapy area. Instead, it combines generics with specialty medicines, which gives it a wider customer base and more ways to serve different price points. In practical terms, generics support volume and access, while specialty products support differentiation and potentially better margins. That mix matters because it reduces dependence on any single product line and makes the company more resilient when one segment faces pricing pressure or patent loss.

The portfolio also supports cross-market reach. A broad set of medicines can serve retail pharmacies, hospitals, wholesalers, and public health systems. For academic work, this is important because it shows how a company can build strategic strength from product diversity rather than from one blockbuster drug. Viatris's model is not pure innovation and not pure commoditization. It sits between the two.

• Generics support volume-based sales and market breadth.
• Specialty medicines support differentiation and stronger pricing power.
• A mixed portfolio lowers concentration risk compared with a single-therapy company.

Innovation-led growth with lower early-stage risk is another part of the value proposition. Viatris can pursue growth through later-stage development, lifecycle management, and targeted specialty expansion without relying only on large, uncertain discovery programs. That matters because early-stage pharmaceutical R&D has high failure risk, long timelines, and heavy cash needs. A model weighted toward approved products and advanced-stage assets usually carries less scientific uncertainty than a company built around early discovery.

This does not mean the company has no innovation exposure. It means the innovation profile is more selective. For investors and researchers, that usually implies a different risk-return structure: less upside from a major first-in-class breakthrough, but also less downside from repeated clinical failures. In plain English, Viatris tries to grow by improving and expanding known commercial platforms rather than by betting everything on unproven science.

Reliable supply to about 1 billion patients is a value proposition on its own. In medicines, supply reliability is not a side issue. If a product is unavailable, the patient and the buyer lose trust immediately. A company serving such a large patient base must manage manufacturing, quality control, sourcing, and distribution with discipline. That matters because a low-cost medicine has limited value if it cannot be delivered consistently.

The reliability message also supports institutional buying decisions. Health systems and distributors need predictable supply because stock-outs can interrupt therapy and raise replacement costs. For Viatris, this creates a non-price advantage: even when multiple suppliers compete on cost, the one that can deliver consistently has a stronger commercial position. In academic terms, this is a mix of operational capability and customer trust.

Supply-related value point	Business impact
About 1 billion patients	Requires large-scale manufacturing and distribution discipline
165+ countries and territories	Requires regulatory, logistics, and quality consistency across markets
Affordable medicines	Pricing advantage only works if supply stays reliable

Higher-growth focus in ophthalmology, dermatology, and gastroenterology gives Viatris a more selective specialty direction. These three areas matter because they can support stronger growth than mature generics markets, especially when products have clear clinical use and recurring demand. The company's strategy in these areas reflects a move toward more differentiated medicines where brand, clinical profile, and physician adoption matter more than low-cost manufacturing alone.

In strategic terms, this focus helps balance the portfolio. Ophthalmology can bring recurring treatment demand. Dermatology can offer broad outpatient use. Gastroenterology can support chronic or repeated treatment patterns. Together, these areas can improve the company's growth profile without requiring a full shift away from generics. For academic analysis, this is a useful example of a hybrid business model: one part access-driven, one part specialty-driven.

• Ophthalmology supports specialty differentiation and repeated patient use.
• Dermatology supports outpatient demand and broad physician adoption.
• Gastroenterology supports chronic-care demand and recurring use.

Viatris's value proposition works because it combines scale, breadth, reliability, and selective specialty growth. The company is not selling a single promise. It is selling access, continuity, and a portfolio that can serve both price-sensitive and growth-oriented markets.

Viatris Inc. - Canvas Business Model: Customer Relationships

Viatris Inc. builds customer relationships through long-term supply contracts, tender-based selling, compliance-heavy product support, and regular engagement with healthcare providers, while also keeping investor attention on cash returns through dividends and buybacks.

Its customer model is not built on brand loyalty in the consumer sense. It is built on continuity, regulatory reliability, delivery performance, and price discipline across large institutional buyers, health systems, governments, distributors, and prescribers.

Relationship type	How it works	Why it matters
Long-term supply agreements	Multi-period contracts with large buyers for steady product supply	Supports volume stability and lowers demand volatility
Regulated product support	Quality, labeling, pharmacovigilance, and compliance support	Required for market access and repeat purchasing
Tender and contract-based selling	Bids and negotiated contracts with institutions and public buyers	Drives access to large-volume accounts
Healthcare provider engagement	Medical information and product-use support for clinicians	Supports prescribing and product adoption
Investor return focus	Dividend payments and share repurchases	Shapes shareholder relationship and capital allocation

Long-term supply agreements are central to Viatris because many of its products are sold into channels that need dependable replenishment. In this model, the customer values supply certainty, regulatory compliance, and price discipline as much as the product itself. For an academic paper, this shows that the relationship is transactional on price but relational on execution.

The company's customer base is broad and institutional. That usually means the buying decision sits with procurement teams, not end users. In practice, this makes service levels, fill rates, quality assurance, and on-time delivery part of the relationship. A failure in one of these areas can affect contract renewal, formulary access, or tender eligibility.

• Large-volume customers often buy through fixed terms rather than open-ended spot purchases.
• Supply reliability matters because many healthcare products cannot be substituted quickly.
• Contract renewal depends on price, quality record, and regulatory compliance.

Regulated, compliance-driven product support is a core relationship feature because Viatris operates in pharmaceuticals, where the customer relationship continues after the sale. Customers need product information, safety updates, adverse event handling, quality documentation, and support for audits or inspections. These are not optional service layers. They are part of the license to operate.

This relationship model also reduces room for informal selling. A healthcare customer will often require documentation that confirms manufacturing standards, traceability, and consistency. That means trust is built through repeat compliance performance, not marketing claims. For research work, this is important because it shows how regulation shapes the structure of customer relationships in pharma.

Tender and contract-based institutional selling is another major channel. In this setup, the customer is often a hospital system, government purchaser, pharmacy benefit entity, or group purchasing organization. The buying process is formal and price sensitive. The company wins business by meeting technical specifications, regulatory requirements, and commercial terms inside a bidding process.

The table below maps the relationship logic to the commercial outcome.

Customer group	Relationship form	Commercial effect
Wholesalers and distributors	Supply contracts and replenishment agreements	Supports steady product flow
Hospitals and health systems	Tenders and formulary-based contracts	Drives large-volume placements
Governments and public purchasers	Bid-based procurement	Creates price pressure but can lock in volume
Healthcare providers	Medical and product-use engagement	Supports confidence in product selection

Ongoing engagement with healthcare providers matters because physicians, pharmacists, and hospital decision-makers influence which products get used. Even when the final purchase is made by a procurement team, clinical acceptance still matters. Viatris must maintain medical communication that supports appropriate use, safety, and continuity of care.

This type of relationship is usually less visible than consumer marketing, but it is more important in pharmaceuticals. If providers trust the product quality, dosing consistency, and safety profile, that lowers switching friction. In academic analysis, this is a good example of how business-to-business healthcare selling depends on clinical credibility as well as pricing.

• Provider trust affects formulary placement.
• Clinical support affects adoption after a procurement award.
• Safety and quality communication affects retention of institutional accounts.

Viatris also maintains a relationship with shareholders through capital returns. The company paid a quarterly dividend of $0.12 per share. On an annualized basis, that equals $0.48 per share if the rate is held for four quarters.

That matters because investor expectations are tied to cash generation, debt discipline, and capital allocation. In plain English, dividends are cash paid directly to shareholders, while buybacks reduce the number of shares outstanding if management repurchases stock. Both are ways of returning money to owners instead of keeping all cash inside the business.

• $0.12 quarterly dividend per share
• $0.48 annualized dividend per share
• Share repurchases support per-share earnings if done below intrinsic value
• Dividend continuity signals cash flow confidence

For a Business Model Canvas analysis, Viatris' customer relationships are best described as high-compliance, low-emotion, contract-led relationships. The company does not rely on frequent consumer interaction. It relies on repeat institutional buying, regulatory trust, and operational consistency.

That means relationship strength depends less on brand storytelling and more on measurable performance: supply continuity, contract wins, regulatory standing, and cash returns to shareholders.

Viatris Inc. - Canvas Business Model: Channels

Viatris Inc. uses a mix of direct commercial selling, third-party distribution, public-sector tendering, and regulatory filing routes to move products into more than 165 countries and territories. Its channel design reflects a portfolio that includes branded, generic, and complex products, with a reported workforce of about 38,000 employees and 2024 net sales of $14.7 billion.

Direct global commercial sales force is the main channel for products that need account management, medical education, and local market access work. This channel matters because prescription medicines often depend on physician adoption, formulary placement, and hospital procurement decisions, not just price. Viatris uses in-country commercial teams in its key markets to support brand retention, product launches, contract renewals, and tender execution. For academic analysis, this channel shows how a pharmaceutical company turns scientific products into recurring revenue through relationship-based selling rather than retail advertising alone.

Channel element	Business role	Why it matters
Direct global commercial sales force	Market access, account management, medical engagement	Supports prescription volume, formulary access, and contract retention
Hospital, pharmacy, and wholesaler networks	Physical product distribution and inventory flow	Moves medicines through the supply chain to patients and providers
Government and payer tenders	Bid-based procurement for public buyers and insurers	Drives large-volume sales in price-sensitive markets
Online investor and corporate communications	Disclosure, guidance, earnings access, governance communication	Shapes capital-market confidence and analyst coverage
Regulatory submission channels	Approval, labeling, lifecycle management, and market entry	Required before products can be sold in many markets

Hospital, pharmacy, and wholesaler networks are the core physical distribution channels for most of Viatris Inc.'s portfolio. These networks matter because medicines usually move from manufacturer to wholesaler, then to hospital, retail pharmacy, clinic, or government channel before reaching patients. In practical terms, this means channel performance depends on service levels, fill rates, cold-chain handling where relevant, inventory planning, and country-specific distributor relationships. For generic and off-patent products, these networks are especially important because availability and contract execution often decide market share more than brand advertising.

• Hospital networks support inpatient and specialist use cases.
• Pharmacy networks support community dispensing and repeat prescription volume.
• Wholesalers support scale, reach, and inventory positioning across geographies.
• Distributor relationships reduce the need for Viatris Inc. to build full direct infrastructure in every market.

Government and payer tenders are a major channel in public health systems and large insurance-led markets. This channel is important because the winning bid can lock in volume for a defined period, but usually at a lower unit price. For Viatris Inc., tender participation fits a portfolio that includes high-volume medicines where access and scale matter. Tender channels reward manufacturing reliability, regulatory readiness, pricing discipline, and local compliance. They also increase concentration risk because losing a tender can quickly reduce sales in that market.

Tender channel feature	Typical effect on Viatris Inc.	Strategic implication
Price-based competition	Lower unit margins	Requires cost control and manufacturing efficiency
Large-volume awards	Higher shipment concentration	Can improve plant utilization and planning
Fixed contract terms	More predictable demand during contract life	Supports inventory and production scheduling
Qualification requirements	Higher compliance burden	Rewards regulatory and quality capability

Online investor and corporate communications are a channel to capital markets, not to patients. Viatris Inc. uses its website, earnings materials, SEC filings, and investor relations communications to distribute quarterly and annual results, debt updates, governance information, and strategic disclosures. This channel matters because a company with 2024 net sales of $14.7 billion and complex global operations depends on clear disclosure to support liquidity, valuation, and credit confidence. In academic work, this channel is useful when analyzing transparency, agency risk, and how management explains business performance to shareholders and lenders.

• Quarterly earnings releases communicate sales, margins, cash flow, and guidance updates.
• Annual reports and proxy materials communicate strategy, risk, board governance, and compensation.
• Investor presentations help explain portfolio mix, debt structure, and capital allocation.
• Corporate websites support product, compliance, and sustainability disclosures.

Regulatory submission channels are the formal paths through which Viatris Inc. seeks product approval, label changes, renewals, and manufacturing site approvals. These channels are critical because a pharmaceutical product cannot be marketed in many countries without regulator review. The company must file dossiers with agencies such as the FDA, EMA, and other national regulators, often using region-specific formats and legal requirements. This channel affects time to market, portfolio breadth, and lifecycle value. It also creates a gatekeeping function: without regulatory clearance, no downstream channel can generate revenue.

Regulatory channel	Business purpose	Channel impact
New product filings	Obtain market authorization	Enables initial launch and revenue generation
Variations and amendments	Change labels, sites, or formulations	Supports lifecycle management and supply continuity
Renewals	Maintain existing approvals	Prevents interruption of sales in mature markets
Quality and manufacturing submissions	Document compliance and site readiness	Protects distribution continuity and product supply

Viatris Inc.'s channel structure is tied to scale and geography. With products sold in more than 165 countries and territories, the company needs a layered model: direct teams for strategic accounts, distributors and wholesalers for reach, tenders for public volume, digital disclosure for capital markets, and regulatory filings for legal market access. That mix is what makes the channel side of the Business Model Canvas important for a company with global supply chains and a broad pharmaceutical portfolio.

Viatris Inc. - Canvas Business Model: Customer Segments

Viatris Inc. sells to five main customer groups: patients who need lower-cost medicines, specialty patients in ophthalmology, dermatology, and gastrointestinal care, institutional buyers such as hospitals and pharmacies, payers and government health programs, and international buyers in Greater China and Emerging Markets.

Customer segment	What matters in this segment	Number or factual anchor
Patients needing affordable generic medicines	Price, access, and continued supply of chronic and acute therapies	Generics are the largest prescription volume category in the U.S.; about 90% of prescriptions filled are generic medicines
Specialty patients in ophthalmology, dermatology, and GI	Branded or differentiated therapies with higher clinical complexity	Global disease burden includes about 2.2 billion people with vision impairment or blindness, about 125 million people with psoriasis, and about 10% to 20% of people worldwide with irritable bowel syndrome
Healthcare systems, hospitals, and pharmacies	Reliable supply, formulary access, and procurement economics	U.S. pharmacies dispense billions of prescriptions each year; hospital and chain pharmacy buyers often negotiate at scale
Payers and government health programs	Budget control, substitution, rebates, and reimbursement discipline	Public programs and insurers fund a large share of prescription spending in the U.S. and Europe
International markets, especially Greater China and Emerging Markets	Localized pricing, registration, channel access, and volume growth	Viatris operates in more than 165 countries and territories

Patients needing affordable generic medicines are the core volume segment. This group includes people treating hypertension, diabetes, cholesterol, infection, pain, and other high-prevalence conditions. The business logic is simple: if a medicine is off-patent, stable, and widely prescribed, demand is driven by affordability and availability rather than premium branding. This segment matters because it gives Viatris scale. In the U.S., about 90% of prescriptions are filled with generic medicines, which means the segment is tied to prescription volume rather than high unit pricing.

• Chronic therapy patients who refill monthly or quarterly
• Acute-care patients needing short treatment cycles
• Patients in cost-sensitive markets where out-of-pocket spending is high
• Buyers who switch quickly when price or supply changes

Specialty patients in ophthalmology, dermatology, and GI are a smaller but strategically important segment. These patients usually need disease-specific therapies with stronger clinical differentiation, tighter prescribing control, and more specialist involvement. In ophthalmology, the addressable need is large because about 2.2 billion people worldwide live with vision impairment or blindness. In dermatology, about 125 million people worldwide live with psoriasis. In GI, irritable bowel syndrome affects about 10% to 20% of people globally. These figures matter because they show why specialty demand can remain durable even when generic pricing is under pressure.

• Ophthalmology patients managed by eye-care specialists
• Dermatology patients with chronic inflammatory skin disease
• GI patients needing longer treatment plans and physician follow-up
• Patients who are more dependent on access, diagnosis, and adherence

Healthcare systems, hospitals, and pharmacies are institutional customers that decide access, stocking, and substitution. These buyers do not purchase medicine for personal use; they buy at scale and care about supply continuity, service levels, and contract terms. This segment matters because it shapes which products are available on shelves and on hospital formularies. A single preferred listing can produce large volume, while delisting can cut access fast. For Viatris, this segment is especially important for broad, high-volume products that fit procurement rules and pharmacy purchasing models.

Institutional buyer	Primary buying criterion	Business impact
Hospitals	Clinical use, supply reliability, contract terms	Formulary access can drive large inpatient and discharge volume
Retail pharmacies	Availability, substitution, reimbursement spread	High prescription turnover creates recurring demand
Health systems	Total cost of care, standardization, supplier consistency	Systemwide contracts can lock in volume across many sites

Payers and government health programs are a separate customer segment because they control reimbursement, formulary access, and budget rules. This includes private insurers, pharmacy benefit managers, national health systems, and public programs. Their main objective is to reduce unit cost while keeping clinical coverage intact. That makes them central to Viatris' business model, especially for generic medicines and selected specialty products. This segment matters because a product can have strong clinical demand but weak commercial performance if reimbursement is poor or if preferred placement goes to a cheaper rival.

• Private insurers seeking lower drug spend
• Pharmacy benefit managers managing U.S. formularies
• Government health programs controlling public budgets
• National health systems negotiating price and access

International markets, especially Greater China and Emerging Markets, are important because medicine demand grows with population, diagnosis rates, and access to formal healthcare. Viatris operates in more than 165 countries and territories, so a large part of its customer base sits outside the U.S. Greater China and Emerging Markets tend to be more price-sensitive than mature markets, which strengthens the fit for a company with a broad generics portfolio and selective specialty products. This segment matters because it gives Viatris geographic diversification and exposure to patient populations that are still expanding access to modern medicines.

• Patients in urban and secondary-care markets
• Public and private hospital systems
• Local distributors and pharmacy chains
• Government procurement programs and reimbursement systems

Geographic segment	Why it matters	Real-life anchor
Greater China	Large patient base, pricing pressure, and registration barriers	Needs local channel access and regulatory execution
Emerging Markets	Growth in diagnosis and medicine access	Typically more price-sensitive than U.S. or Western Europe
Developed markets	Volume scale and reimbursement discipline	Generic substitution and payer control drive demand

Viatris Inc. - Canvas Business Model: Cost Structure

$14.7 billion in net sales, $6.7 billion in cost of sales, and $656 million in research and development expense were the main operating-cost anchors in the most recently reported annual period available in Viatris Inc. filings.

Cost item	Amount	Period
Net sales	$14.7 billion	2024
Cost of sales	$6.7 billion	2024
Research and development	$656 million	2024
Selling, general and administrative	$3.3 billion	2024
Restructuring and other charges	$173 million	2024

$6.7 billion of cost of sales reflects the largest direct cost bucket in the model. For a global generic and branded medicines company, this category usually includes active pharmaceutical ingredients, finished-dose manufacturing, packaging, quality control, freight, warehousing, and third-party manufacturing. The size of this line matters because even small changes in plant yield, procurement prices, or freight rates can move gross margin by tens or hundreds of millions of dollars.

Manufacturing and supply chain costs also sit inside cost of sales through inventory and production efficiency. When a company sells across many markets, the cost base is shaped by factory utilization, transfer pricing, and the number of regulated production sites needed to keep products supplied in multiple jurisdictions. For Viatris Inc., this is a structural cost because the portfolio is broad and highly distributed.

• $6.7 billion cost of sales
• $14.7 billion net sales
• 45% cost of sales as a share of net sales, based on $6.7 billion divided by $14.7 billion

Research and development spending was $656 million. In a business model canvas, this is not as large as the manufacturing base, but it still matters because generic substitution, complex generics, biosimilars, and product life-cycle management all depend on development work, formulation studies, and bioequivalence testing. R&D also supports retention of product approvals in regulated markets.

Using the reported numbers, R&D represented 4.5% of net sales, based on $656 million divided by $14.7 billion. That ratio is a useful academic measure because it shows how much of the cost structure is tied to future product support rather than current production.

R&D measure	Amount	Share of net sales
Research and development expense	$656 million	4.5%
Net sales	$14.7 billion	100%

Regulatory filings and approvals add cost through dossier preparation, stability studies, inspections, quality-system maintenance, and country-by-country submissions. These costs are usually embedded in R&D, quality, and legal-compliance spending rather than shown as a separate line item. For a multi-market pharmaceutical company, the cost is recurring because product registrations have to be maintained, renewed, and updated when labels, manufacturing sites, or formulations change.

Facility closures, downsizing, and remediation appear in restructuring and other charges. Viatris Inc. reported $173 million of restructuring and other charges in 2024. These charges matter because they capture the cash and non-cash cost of changing the operating footprint, reducing headcount, closing sites, and fixing environmental or manufacturing issues tied to older assets.

• $173 million restructuring and other charges
• $3.3 billion selling, general and administrative expense
• 22.4% selling, general and administrative expense as a share of net sales, based on $3.3 billion divided by $14.7 billion

Litigation and settlement payments are part of the cost structure because a pharmaceutical company with a large historical product portfolio carries ongoing legal exposure. These costs can include defense spending, accruals, settlements, and insurance recoveries. Where a company does not present a separate annual figure in the same line item, the cost still affects operating income, cash flow, and balance-sheet reserves.

Cost structure component	Reported amount	Analytical point
Manufacturing and supply chain	$6.7 billion	Largest direct cost base
R&D	$656 million	4.5% of net sales
Regulatory work	Included in operating expenses	Embedded in compliance and development spending
Facility closures and remediation	$173 million	Restructuring and other charges
Litigation and settlements	Included in operating expenses and accruals	Cash and reserve impact

The cost structure is therefore dominated by production scale, global distribution, compliance-heavy development, restructuring, and legal exposure. The most visible quantified elements are $6.7 billion in cost of sales, $656 million in R&D, $3.3 billion in SG&A, and $173 million in restructuring and other charges.

Viatris Inc. - Canvas Business Model: Revenue Streams

$15.4 billion in 2023 net sales is the main revenue anchor for Viatris Inc., and the company's commercial footprint spans 165 countries and territories. Revenue comes from a mix of generic prescription medicines, specialty and branded medicines, and launches across multiple international markets.

Revenue stream	Real-life number	Business relevance
Total net sales	$15.4 billion in 2023	Shows the scale of the full portfolio and the size of the company's cash-generating base
Geographic reach	165 countries and territories	Shows how revenue is spread across many markets instead of relying on one country
Revenue mix	Generic prescription medicines, specialty medicines, branded medicines, launches, and international sales	Reduces dependence on a single product type and supports steadier sales

Generic prescription medicine sales are the volume engine of the revenue model. In this type of business, sales usually come from high unit counts and lower prices than branded medicines, so the key driver is market access and scale rather than premium pricing. For Viatris Inc., this matters because generic products can generate recurring revenue across many countries and can keep cash flow coming in even when individual products face pricing pressure.

Specialty and branded medicine sales contribute a different kind of revenue: lower volume, higher value per prescription, and more protection from direct price competition. This stream matters because it can lift margins and reduce pressure from commoditized generic pricing. In a business model canvas, this is the part of the model that helps balance the lower-margin generic base with higher-value products.

• Generic prescription medicines: volume-driven sales
• Specialty medicines: higher-value prescription sales
• Branded medicines: premium-priced prescription revenue
• New launches: incremental sales from recently approved products
• International sales: revenue across 165 countries and territories

New product launches and approvals are important because they replace revenue that can be lost as older products mature. Each new approval adds another product that can be sold through existing commercial channels, which lowers the cost of reaching the market compared with building a new business from scratch. For an academic analysis, this is the clearest link between research, regulation, and revenue growth.

International sales across 165 countries and territories make the company's revenue model globally diversified. This reduces concentration risk and gives the company more than one demand base. It also means revenue can come from multiple reimbursement systems, regulatory regimes, and price environments, which affects both growth and margin structure.

Geographic area	Revenue stream role	Real-life figure
Greater China	Portfolio growth area	Included in the company's 165-country commercial footprint
Emerging Markets	Portfolio growth area	Included in the company's 165-country commercial footprint
Global business	Revenue base	$15.4 billion in 2023 net sales

Portfolio growth in Greater China and Emerging Markets matters because these regions can add new demand sources to the revenue base. In practical terms, growth in these markets helps offset slower sales in more mature markets and supports broader product lifecycle value. For a student paper, this is a useful example of how geography can be part of revenue strategy, not just market expansion.

• $15.4 billion net sales in 2023
• 165 countries and territories served
• Multiple revenue sources across generic, specialty, branded, and launched products
• Growth opportunities tied to Greater China and Emerging Markets